A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

• Status: Recruiting
• Trial end date: 2024-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

This is a multi-centers, randomized, double-blind, parallel-group, Phase 2 Trial to evaluate the efficacy and safety of CKD-498 in female patients with Androgenetic Alopecia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical

Criteria

Key Inclusion Criteria:

• Female of age 19-54 years

• Clinical Diagnosis of Androgenetic Alopecia

• Written informed consent

Key Exclusion Criteria:

• Other types of Alopecia or other diseases that can cause hair loss

• Clinically significant scalp disease such as seborrheic dermatitis or psoriasis

• Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator

• Women who are pregnant or breastfeeding

• Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of study drug